American Medical Association (AMA)

The American Medical Association (AMA) is the largest professional association and lobbying group of physicians and medical students. The AMA mission is to promote the art and science of medicine and the betterment of public health. The association represents physicians with a unified voice in courts and legislative bodies across the nation, removing obstacles that interfere with patient care, leading efforts to prevent chronic disease and confront public health crises, and driving the future of medicine to tackle the biggest challenges in healthcare.

Thumbnail

Cardiologists, cardiac surgeons support new bill that could limit Medicare cuts

More than 100 U.S. medical societies—including the ACC, ASNC and others—have united in support of a new bill that would make a long-term impact on Medicare payments.

Thumbnail

A simple way to help cardiologists communicate with patients

A new JAMA Internal Medicine study suggests that communication coaching for cardiologists may help improve patient interactions by encouraging questions and increasing empathy.

Thumbnail

Industry groups applaud bill connecting Medicare payments to inflation

Healthcare groups are applauding a bill in the House of Representatives that would ensure Medicare payments are tied to inflation.

Thumbnail

Physicians sound off on prior authorization burdens on patients

Recent survey findings underscore that the vast majority of physicians believe prior authorization has a negative impact on patient care. In fact, some specialists think it leads to worse outcomes.

 

Industry groups agree MedPAC’s inflationary update is not enough

The Medicare Payment Advisory Commission (MedPAC) wants to tie physician payments to inflation. Healthcare groups say it doesn't go far enough

U.S. News & World Report children’s hospitals cardiology heart surgery

Children with autism face higher risk of diabetes, heart disease, dyslipidemia

Researchers examined data from 34 different studies, publishing their full systematic review and meta-analysis in JAMA Pediatrics.

Thumbnail

High costs limit the value of dapagliflozin, empagliflozin as heart failure treatments

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more. 

The increased use of implantable loop recorders (ILRs) is associated with identifying more bradyarrhythmias such as bradycardia, according to new findings published in JAMA Cardiology.

Increased AFib screening improves bradyarrhythmia detection—but is it a mixed blessing?

When long-term continuous monitoring detects bradyarrhythmia in an asymptomatic patient, is it still providing value?